Treatment options in Crohn’s disease (CD) are limited. Tofacitinib, a Janus Kinase 1-3 inhibitor, is not currently approved for use in CD, however, its effect on biochemical markers suggests that tofacitinib does impact disease activity in CD.
Treatment options in Crohn’s disease (CD) are limited. Tofacitinib, a Janus Kinase 1-3 inhibitor, is not currently approved for use in CD, however, its effect on biochemical markers suggests that tofacitinib does impact disease activity in CD.